Cristian Massacesi, M.D., is a distinguished oncologist and pharmaceutical executive serving as Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb (BMS). A native of Argentina, he earned his medical degree from the University of Buenos Aires School of Medicine and completed his residency in internal medicine and fellowship in medical oncology at the Instituto de Oncología Ángel H. Roffo. Early in his career, Massacesi held clinical and leadership roles in Latin America and Europe, including positions at AstraZeneca where he advanced oncology programs and built expertise in immuno-oncology and targeted therapies. Before joining BMS in 2021, Massacesi spent nearly a decade at Novartis, rising to Senior Vice President and Global Head of Oncology Clinical Development, Immunology, and Cell & Gene Therapies. There, he spearheaded the development of groundbreaking therapies, including CAR-T cell treatments like Kymriah and innovative immuno-oncology combinations, contributing to multiple regulatory approvals and pivotal clinical trials that transformed cancer care. His strategic leadership accelerated pipeline progression, fostering collaborations that integrated novel modalities such as bispecific antibodies and next-generation immunotherapies. At BMS, Massacesi oversees the company's global development organization, encompassing clinical research, regulatory affairs, and biometrics for a robust portfolio exceeding 50 programs across oncology, immunology, and other therapeutic areas. Under his guidance, BMS has advanced high-impact assets like Opdivo-based combinations, Breyanzi cell therapy, and emerging modalities in tumor microenvironment modulation. His visionary approach emphasizes patient-centric innovation, data-driven decision-making, and cross-functional integration to deliver transformative medicines, solidifying BMS's position as a leader in precision oncology.